Last10K.com

Marina Biotech, Inc. (MRNA) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Adhera Therapeutics, Inc.

CIK: 737207
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Apr. 16, 2018
Jun. 30, 2017
Document And Entity Information   
Entity Registrant NameMarina Biotech, Inc.  
Entity Central Index Key0000737207  
Document Type10-K  
Document Period End DateDec. 31, 2017  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilerNo  
Entity's Reporting Status CurrentYes  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 19,500,000
Entity Common Stock, Shares Outstanding 10,521,278 
Trading SymbolMRNA  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2017  

View differences made from one year to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..

Continue

Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Shareholders' Deficiency
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Income Taxes
Income Taxes (details Narrative)
Income Taxes (tables)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (details)
Intangible Assets
Intangible Assets (details Narrative)
Intangible Assets (tables)
Intangible Assets - Schedule Of Estimate Fair Value Of Assets Acquired And Liabilities (details)
Intangible Assets - Schedule Of Intangible Assets (details)
Intangible Assets - Schedule Of Merger Agreement Based On Common Stock Outstanding (details)
Intellectual Property And Collaborative Agreements
Intellectual Property And Collaborative Agreements (details Narrative)
Notes Payable
Notes Payable (details Narrative)
Notes Payable (tables)
Notes Payable - Summary Of Notes Payable (details)
Notes Payable - Summary Of Notes Payable (details) (parenthetical)
Organization And Business Operations
Related Party Transactions
Related Party Transactions (details Narrative)
Stock Incentive Plans
Stock Incentive Plans (details Narrative)
Stock Incentive Plans (tables)
Stock Incentive Plans - Schedule Of Stock Option Activity (details)
Stock Incentive Plans - Schedule Of Summary Of Additional Information On Stock Options Outstanding (details)
Stockholders' Equity
Stockholders' Equity (details Narrative)
Stockholders' Equity (tables)
Stockholders' Equity - Schedule Of Warrant Activity (details)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Anti-dilutive Securities (details)
Summary Of Significant Accounting Policies - Schedule Of Fair Value Liability Of Price Adjustable Warrants Determined By Level 3 (details)
Summary Of Significant Accounting Policies - Schedule Of Liabilities Measured At Fair Value On Recurring Basis (details)
CIK: 737207
Form Type: 10-K Annual Report
Accession Number: 0001493152-18-005372
Submitted to the SEC: Tue Apr 17 2018 5:32:24 PM EST
Accepted by the SEC: Tue Apr 17 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/737207/0001493152-18-005372.htm